Incidental Investigational Work

Investigational Approaches for Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the development of more effective treatment approaches for patients with MPM. This review will provide a comprehensive state of the art of new investigational a...

Antiretroviral Chemotherapy: New Investigational Agents

As in previous years, the 9th Conference on Retroviruses and Opportunistic Infections provided a forum for a stateof-the-art update in antiretroviral therapy. Highlights included the status of new antiretroviral agents from both existing and new drug classes; presentation of trials in antiretroviral-naive and antiretroviral-experienced persons; updates on strategic approaches to therapy, includ...

Development of investigational radiation modifiers.

Historically, clinically useful modifiers of radiation therapy have been conventional chemotherapeutic agents (e.g., 5-fluorouracil and thymidylate synthase inhibitors, cisplatin and related compounds, and taxanes) (1–4) administered on a schedule designed to optimize the interaction between the agent and radiation. The Cancer Therapy Evaluation Program (CTEP) and the Radiation Research Program...

Investigational drugs and the law.

The regulation of investigational drugs.

THE search for effective drugs to combat the acquired immunodeficiency syndrome (AIDS) has focused renewed attention on the process by which the U.S. Food and Drug Administration(FDA) regulates the development and availability of new therapeutic agents. The federal government’s ability to strike the difficult balance between ensuring the safety of patients and accelerating the availability of n...